Automated Nanoparticle System Consistent Lipid Nanoparticle and Liposome Preparation
Dolomite Microfluidics is leading the way in nanoparticle production with the release of its Automated Nanoparticle (ANP) System for microfluidic formulation library generation. This automated platform is the result of a four-year focus on the challenges commonly associated with batch production of lipid nanoparticles and liposomes for drug and vaccine development, including inconsistent particle size and poor encapsulation efficiency.
Royston/UK — Liposomes and lipid nanoparticles are becoming increasingly important in a wide range of industries, particularly pharmaceuticals, where they can be used as drug delivery vehicles or to encapsulate vaccines, including for Covid-19. The new ANP System launched by Dolomite Microfluidics is to provide researchers with a tool for more efficient and cost-effective protocol development, offering an alternative to commonly used IP licensing models for library creation and freeing up time for other lab processes.
The modular ANP System is designed to fill a gap in the marketplace for customers wanting to progress through the protocol development pipeline without changing their system entirely, or to generate nanoparticles at small scale using reduced quantities of precious cargo. Its microfluidic approach allows rapid and reproducible generation of highly monodisperse particles from 40 to 800 nm, with enhanced encapsulation efficiency. Lipid solutions and cargoes are loaded directly into sample loops, automatically injected into the system, and the resulting liposomes are collected in individual vials to avoid cross-contamination. The ANP System is available for process optimization and fully automated for walk-away library generation.